Market Place
Sourcing Support
All News #Library
Biotech
Hepta Reveals Multi-Omic Atlas Linking Liver Pathway Biology
10 Nov 2025 //
BUSINESS WIRE
Akero Shares New Analyses From Ph2b SYMMETRY And HARMONY Trials
07 Nov 2025 //
GLOBENEWSWIRE
Novo Strikes Up To $5.2B Deal For Akero In Red-Hot MASH Space
11 Oct 2025 //
BIOSPACE
Akero Therapeutics To Unveil Phase 2B Efruxifermin Data At AASLD
07 Oct 2025 //
GLOBENEWSWIRE
How Akero’s MASH Success Drove Roche’s $3.5B Takeout of 89bio
03 Oct 2025 //
BIOSPACE
Akero Therapeutics to Present at Morgan Stanley Health Conference
28 Aug 2025 //
GLOBENEWSWIRE
Akero Announces Publication of The Phase 2b Harmony Trial
14 Aug 2025 //
GLOBENEWSWIRE
Akero Therapeutics Announces Q2 2025 Financial Results and Update
08 Aug 2025 //
GLOBENEWSWIRE
Apple Tree Lawsuit Says Portfolio Biotechs Face Collapse
30 Jun 2025 //
FIERCE BIOTECH
Akero Therapeutics Reports Q1 2025 Results and Business Update
12 May 2025 //
GLOBENEWSWIRE
Akero, HistoIndex Share Ph 2b Harmony Data at EASL 2025
10 May 2025 //
GLOBENEWSWIRE
Akero Therapeutics presents Week 96 results from Phase 2b SYMMETR
09 May 2025 //
GLOBENEWSWIRE
Akero`s stock doubles as midphase MASH trial hits the mark
28 Jan 2025 //
FIERCE BIOTECH
Akero Reports MASH Cirrhosis Reversal In Phase 2b Symmetry Study
27 Jan 2025 //
GLOBENEWSWIRE
Akero Completes Ph 3 Synchrony Enrollment For Efruxifermin In MASH
13 Jan 2025 //
GLOBENEWSWIRE
Akero Presents Efruxifermin Data At AASLD The Liver Meeting 2024
21 Oct 2024 //
GLOBENEWSWIRE
Akero Announces First Patient Dosed In SYNCHRONY Study
09 Sep 2024 //
GLOBENEWSWIRE
Akero Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
18 Dec 2023 //
GLOBENEWSWIRE
Akero Announces Positive SYNCHRONY Phase 3 Program for Efruxifermin
29 Mar 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.